论文部分内容阅读
为更好地了解肾细胞癌的发病机制 ,应用免疫组化技术方法 ,检测 47例肾细胞癌中bcl_2、ki_6 7和P5 3蛋白表达 ,并分析其临床意义。结果 :bcl_2、ki_6 7和P5 3表达在不同细胞类型中无明显差异 ,病理分级中 ,bcl_2阳性率随分级升高而降低 ,ki_6 7和P5 3表达率则随分级升高而增高 ;不同临床分期中 ,ki_6 7和bcl_2表达率无统计学差别 ,但P5 3阳性率在临床I期明显高于其它各期 ;bcl_2、ki_6 7和P5 3阳性和阴性标本中 ,术后 5年生存率差异无显著性 ,但ki_6 7阳性组 5年生存率明显降低。结论 :bcl_2、ki_6 7和P5 3表达在RCC发生中有一定作用 ,但与RCC细胞分类无关 ,bcl_2表达在细胞癌变早期有一定作用 ,ki_6 7表达率升高与细胞恶性程度和预后不良有关 ,P5 3蛋白表达多出现于RCC临床早期阶段 ,故有一定诊断意义
In order to better understand the pathogenesis of renal cell carcinoma, the expression of bcl-2, ki-67 and P53 in 47 cases of renal cell carcinoma was detected by immunohistochemistry and its clinical significance was analyzed. Results: There was no significant difference in the expression of bcl_2, ki_6 7 and P5 3 in different cell types. The positive rate of bcl_2 in the pathological grade decreased with the increase of grade, while the expression rates of ki_6 7 and P5 3 increased with the increase of grade. There was no significant difference in the expression rates of ki 6 7 and bcl 2 between the two groups, but the positive rate of P 5 3 in clinical phase I was significantly higher than that in other phases. The difference of 5-year survival rates between bcl 2, ki 6 7 and P 5 3 positive and negative specimens No significant, but the ki 6 positive group 5-year survival rate was significantly lower. CONCLUSION: The expressions of bcl_2, ki_6 7 and P5 3 play a role in the development of RCC. However, the expression of bcl_2 is not related to the classification of RCC. The expression of bcl_2 may play an important role in the early stage of cell carcinoma. The increased expression of ki_6 7 is related to the malignancy and poor prognosis. P5 3 protein expression appeared in the early stages of RCC clinical, it has some diagnostic significance